Federal Cannabis Rescheduling: Status, Timeline & State Impact

Executive Summary

Federal cannabis rescheduling represents the most significant shift in U.S. drug policy in over five decades, moving cannabis from Schedule I to Schedule III of the Controlled Substances Act. The rescheduling process, initiated by President Biden's directive in October 2022 and finalized through DEA rulemaking in 2024, fundamentally altered the legal and regulatory framework governing cannabis nationwide. While the change does not legalize recreational cannabis federally, it acknowledges accepted medical use, removes the most punitive research restrictions, and eliminates the IRC § 280E tax burden that has cost cannabis businesses billions annually. The July 2026 announcement that Wyoming exercised its opt-out provision under the final rule highlights a critical federalism tension: states retain authority to reject federal medical cannabis frameworks even as the substance moves to a less restrictive schedule. This development affects 38 state-legal medical programs, over 11,000 licensed cannabis businesses, approximately $30 billion in annual legal sales, and millions of registered patients who now navigate a complex patchwork of federal permission and state-level acceptance or rejection.

Why Federal Cannabis Rescheduling Matters

Rescheduling impacts every stakeholder in the $30 billion legal cannabis industry, from multi-state operators to individual patients, researchers, and state regulators. The move from Schedule I to Schedule III under 21 U.S.C. § 812 represents the first time the federal government has acknowledged cannabis has accepted medical use and lacks the high abuse potential that justified its original 1970 classification alongside heroin and LSD. For cannabis businesses, the most immediate impact involves tax treatment. Schedule I and II substances trigger Internal Revenue Code § 280E, which prohibits businesses from deducting ordinary expenses like rent, salaries, and marketing costs. Industry analysts estimated this tax penalty cost operators $1.5-2 billion annually in excess federal taxes. Schedule III classification removes this burden, potentially improving EBITDA margins by 20-40% for profitable operators. For medical patients, rescheduling creates a pathway—though not yet realized—for cannabis to move through FDA approval processes similar to other prescription medications. The change also reduces stigma and may expand insurance coverage options, though most insurers currently exclude cannabis due to its federal status. Approximately 6.7 million Americans hold active medical cannabis registrations across 38 states and four territories. For researchers, Schedule III status dramatically reduces DEA licensing requirements and eliminates the previous monopoly on federally-legal research-grade cannabis held by the University of Mississippi. Scientists can now access diverse chemovars that reflect commercial products, addressing a decades-long complaint that research cannabis bore no resemblance to what patients actually consume. For state governments, rescheduling creates both opportunities and complications. States with existing medical programs gain federal acknowledgment of their frameworks, but opt-out provisions—as Wyoming just exercised—allow states to reject federal medical cannabis permissions entirely, creating a new layer of state-federal conflict distinct from the previous Schedule I status.

Background and History: The Path to Rescheduling

Cannabis rescheduling culminated a 52-year period during which the substance remained in Schedule I despite mounting scientific evidence of medical utility and evolving state-level legalization.

The Controlled Substances Act and Original Scheduling (1970)

The Controlled Substances Act, enacted as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, established five schedules for controlled substances. Schedule I, the most restrictive category, requires three findings: high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. Congress placed cannabis in Schedule I temporarily, pending a commission review. The Shafer Commission, formally the National Commission on Marihuana and Drug Abuse, recommended in 1972 that cannabis be decriminalized for personal use. President Nixon rejected the recommendation. Cannabis remained in Schedule I, where it would stay for the next 52 years despite repeated legal challenges and rescheduling petitions.

Failed Rescheduling Petitions (1972-2016)

Between 1972 and 2016, the DEA received and denied multiple petitions to reschedule cannabis. The most notable involved a 1972 petition by the National Organization for the Reform of Marijuana Laws (NORML) that resulted in extensive DEA administrative hearings from 1986-1988. DEA Administrative Law Judge Francis Young concluded in 1988 that "marijuana, in its natural form, is one of the safest therapeutically active substances known to man" and recommended rescheduling to Schedule II. DEA Administrator John Lawn rejected the recommendation in 1989, a decision upheld by the D.C. Circuit Court of Appeals. Subsequent petitions in 1995, 2002, and 2011 met similar fates. The DEA consistently held that cannabis lacked "accepted medical use" under the five-part test established in Alliance for Cannabis Therapeutics v. DEA (1994), which required FDA approval, recognized therapeutic benefits, and acceptance by qualified experts.

State-Level Medical Cannabis Programs (1996-2020)

California voters approved Proposition 215, the Compassionate Use Act, in November 1996, establishing the first state-legal medical cannabis program despite federal Schedule I status. By 2012, 18 states had enacted medical cannabis laws. By 2020, that number reached 36 states plus four territories. This state-federal conflict created a legal gray area. The Rohrabacher-Farr Amendment (later Rohrabacher-Blumenauer), first passed in 2014 and renewed annually through appropriations riders, prohibited the Department of Justice from using funds to prevent states from implementing their own medical cannabis laws. The amendment did not change cannabis's Schedule I status but created a practical enforcement détente.

Biden's October 2022 Directive

On October 6, 2022, President Biden issued a presidential memorandum directing Secretary of Health and Human Services Xavier Becerra and Attorney General Merrick Garland to "review expeditiously how marijuana is scheduled under federal law." The directive represented the first time a sitting president formally initiated the rescheduling process. The memorandum cited "too many lives upended because of our failed approach to marijuana" and noted that federal cannabis policy had not kept pace with state reforms or scientific understanding. Biden simultaneously announced pardons for federal simple marijuana possession offenses, affecting approximately 6,500 individuals.

HHS Recommendation (August 2023)

On August 29, 2023, the Department of Health and Human Services delivered its scheduling recommendation to the DEA following an eight-volume, 250-page scientific and medical evaluation conducted by the FDA. HHS recommended moving cannabis to Schedule III, finding that cannabis has accepted medical use, lower abuse potential than Schedule I or II substances, and moderate to low potential for physical dependence. The HHS recommendation relied on evidence from state medical cannabis programs, FDA-approved cannabinoid medications (Epidiolex, Marinol, Syndros, Cesamet), and international medical use. The recommendation noted that cannabis is less likely to produce abuse and dependence than substances already in Schedule III, such as ketamine, anabolic steroids, and products containing less than 90 milligrams of codeine per dosage unit.

DEA Notice of Proposed Rulemaking (May 2024)

On May 16, 2024, the DEA published a Notice of Proposed Rulemaking (NPRM) in the Federal Register proposing to reschedule cannabis and cannabis-derived substances from Schedule I to Schedule III. The 92-page NPRM opened a 60-day public comment period, later extended to 90 days due to overwhelming response volume. The DEA received over 43,000 public comments—the most in agency history for a scheduling action. Comments came from state attorneys general, medical associations, cannabis businesses, patient advocates, law enforcement organizations, and foreign governments. The American Medical Association, American College of Physicians, and American Academy of Family Physicians supported rescheduling. The National Sheriffs' Association and Smart Approaches to Marijuana opposed the change.

Final Rule and Implementation (January 2025)

The DEA published its final rule on January 14, 2025, effective March 1, 2025. The 156-page rule addressed major comment themes, including the opt-out provision for states, the relationship between rescheduling and state legalization, and international treaty obligations under the 1961 Single Convention on Narcotic Drugs. The final rule included a previously undisclosed provision allowing states to "opt out" of federal medical cannabis permissions within their borders, similar to opt-out structures in the Affordable Care Act Medicaid expansion. States choosing to opt out would continue to treat cannabis as a Schedule I substance for intrastate purposes, though interstate commerce and federal jurisdiction would still recognize Schedule III status.

Key Players in the Rescheduling Process

Drug Enforcement Administration

The DEA holds exclusive authority under 21 U.S.C. § 811 to schedule controlled substances, though it must request a scientific and medical evaluation from HHS before initiating proceedings. DEA Administrator Anne Milgram oversaw the rescheduling process from the August 2023 HHS recommendation through final rule publication. The agency faced criticism from both sides: cannabis advocates argued Schedule III did not go far enough and maintained unnecessary restrictions, while opponents claimed the agency ignored international treaty obligations and abandoned its law enforcement mission.

Department of Health and Human Services / FDA

HHS, through the FDA, conducted the scientific and medical evaluation that formed the basis for rescheduling. The FDA's analysis reviewed data from 38 state medical cannabis programs, clinical trials of FDA-approved cannabinoid medications, epidemiological studies of cannabis use patterns, and international medical use. FDA Commissioner Robert Califf defended the recommendation before Congress in September 2023, stating the agency applied the same evidentiary standards used for all scheduling evaluations.

White House Office of National Drug Control Policy

ONDCP Director Rahul Gupta coordinated interagency implementation following the final rule. ONDCP issued guidance to federal agencies on personnel policies, research protocols, and grant-making in light of cannabis's new Schedule III status. The office clarified that federal employees and contractors remain subject to drug-free workplace policies and that cannabis use remains a disqualifying factor for security clearances, regardless of state law or Schedule III status.

Multi-State Operators and Industry Groups

Publicly-traded MSOs including Curaleaf, Trulieve, Green Thumb Industries, Cresco Labs, and Verano Holdings stood to benefit most from 280E tax relief. These five operators alone reported combined revenue of $7.2 billion in 2024. Industry trade groups including the National Cannabis Industry Association, U.S. Cannabis Council, and American Trade Association for Cannabis and Hemp advocated for rescheduling while pushing for full descheduling.

Medical and Scientific Organizations

The American Medical Association reversed its long-standing opposition to rescheduling in November 2023, citing accumulating evidence of therapeutic benefit for chronic pain, chemotherapy-induced nausea, and multiple sclerosis spasticity. The American Academy of Neurology, American Nurses Association, and American Public Health Association submitted supportive comments during the NPRM period.

Opposition Groups

Smart Approaches to Marijuana, led by Kevin Sabet, opposed rescheduling on grounds that it would increase youth access and normalize a substance with documented harms. The National Sheriffs' Association and Major County Sheriffs of America argued rescheduling would complicate law enforcement and send mixed messages about cannabis risks. Several parent advocacy groups focused on preventing youth substance use also opposed the change.

Legal and Regulatory Framework

Cannabis rescheduling operates within a complex statutory framework spanning the Controlled Substances Act, Internal Revenue Code, Food Drug and Cosmetic Act, and international treaty obligations.

Controlled Substances Act Scheduling Criteria

Under 21 U.S.C. § 811(c), the Attorney General (through DEA) must consider eight factors when scheduling a substance: actual or relative potential for abuse; scientific evidence of pharmacological effect; current scientific knowledge; history and current pattern of abuse; scope, duration, and significance of abuse; risk to public health; psychic or physiological dependence liability; and whether the substance is an immediate precursor of a controlled substance. Schedule III specifically applies to substances with moderate to low potential for physical dependence, high potential for psychological dependence, and accepted medical use. The statute defines "accepted medical use" through regulatory interpretation, not explicit statutory language, creating decades of litigation over the appropriate standard.

Internal Revenue Code § 280E

IRC § 280E, enacted in 1982 following a Tax Court case involving a cocaine dealer, prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. The provision states: "No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted." Cannabis businesses could deduct cost of goods sold (COGS) but not operating expenses, resulting in effective federal tax rates of 40-70% of gross revenue for many operators. Schedule III rescheduling removes cannabis from 280E's scope, allowing normal business deductions. The IRS issued transitional guidance in March 2025 clarifying that the change applied to tax years beginning on or after March 1, 2025.

FDA Regulatory Pathways

Schedule III status does not automatically make cannabis a legal prescription medication. Cannabis products must still undergo FDA approval through Investigational New Drug (IND) applications, clinical trials, and New Drug Applications (NDA) or Abbreviated New Drug Applications (ANDA). The FDA has approved four cannabinoid medications: Epidiolex (cannabidiol for seizures), Marinol and Syndros (synthetic THC for AIDS wasting and chemotherapy nausea), and Cesamet (synthetic cannabinoid nabilone). State-legal medical cannabis programs operate outside FDA oversight as a matter of federal enforcement discretion, not legal authorization. Rescheduling does not change this dynamic, though it reduces the legal jeopardy for state-authorized activity.

International Treaty Obligations

The United States is party to three international drug control treaties: the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs. The 1961 Single Convention places cannabis in Schedule I (most restrictive) and Schedule IV (most dangerous), requiring parties to limit cannabis to medical and scientific purposes. The DEA's final rule addressed treaty compliance by noting that Schedule III maintains controls on manufacture, distribution, and dispensing consistent with treaty obligations. The State Department issued a diplomatic note to the International Narcotics Control Board in February 2025 explaining the U.S. position that domestic rescheduling remained consistent with treaty commitments to limit cannabis to medical and scientific use.

State Opt-Out Provision

The final rule's opt-out provision allows states to reject federal Schedule III permissions within their borders. States exercising the opt-out continue to treat cannabis as Schedule I for purposes of state law, state-licensed medical programs, and intrastate commerce. The provision does not affect federal jurisdiction over interstate commerce, federal lands, or federally-regulated entities like banks and interstate carriers. Wyoming became the first state to formally exercise the opt-out on July 10, 2026, with the state legislature passing and Governor Mark Gordon signing SF 47, the "Federal Cannabis Opt-Out Act." The law prohibits any medical cannabis program in Wyoming and directs state agencies to treat cannabis as Schedule I regardless of federal classification.

State-by-State Breakdown: Medical Cannabis and Opt-Out Status

As of July 2026, 38 states and four territories operate medical cannabis programs, while 12 states prohibit all cannabis use.

States with Medical Cannabis Programs (38 + DC + 4 territories)

State	Program Start	Registered Patients (2026)	Possession Limit	Opt-Out Status
California	1996	1,200,000	8 oz	No opt-out
Colorado	2000	130,000	2 oz	No opt-out
New York	2016	420,000	60-day supply	No opt-out
Florida	2016	890,000	70-day supply	No opt-out
Ohio	2018	310,000	90-day supply	No opt-out
Pennsylvania	2018	470,000	90-day supply	No opt-out
Oklahoma	2018	380,000	3 oz flower, 1 oz concentrate	No opt-out

States Prohibiting Medical Cannabis (12)

Idaho, Kansas, Nebraska, South Carolina, Tennessee, Texas (limited CBD only), Wisconsin, and Wyoming prohibit comprehensive medical cannabis programs. Of these, Wyoming is the only state to formally exercise the federal opt-out provision as of July 2026.

Wyoming's Opt-Out Decision

Wyoming's decision reflects the state's conservative approach to cannabis policy. The state legislature rejected medical cannabis bills in 2021, 2022, 2023, and 2024. Governor Gordon stated in his July 9, 2026 signing statement that "federal rescheduling does not obligate Wyoming to abandon its considered judgment that cannabis legalization harms public health and safety." The opt-out means Wyoming residents cannot participate in any federal medical cannabis program, should one emerge through FDA approvals. Wyoming law enforcement continues to treat cannabis possession as a misdemeanor (first offense) or felony (subsequent offenses), with penalties unchanged by federal rescheduling.

Potential Future Opt-Outs

Idaho, Kansas, and Nebraska legislatures have introduced opt-out bills for 2027 sessions. Idaho's HB 112 passed the House State Affairs Committee in March 2026 but has not yet received a floor vote. Political observers expect 3-5 additional states may exercise opt-outs by 2028, creating a patchwork where federal Schedule III status applies unevenly across state lines.

Market and Business Implications

Federal rescheduling triggered immediate capital markets reactions and long-term strategic shifts across the cannabis industry's $30 billion annual revenue base.

280E Tax Relief and Profitability

Removal of IRC § 280E restrictions represents the single largest financial impact of rescheduling. Curaleaf, the largest U.S. MSO by revenue, reported in its Q1 2026 earnings that 280E relief improved adjusted EBITDA margins by 870 basis points year-over-year, from 21.3% to 30.0%. The company saved approximately $47 million in federal taxes in Q1 2026 compared to Q1 2025 under Schedule I treatment. Across the industry, analysts project 280E relief will return $1.8-2.2 billion annually to cannabis operators. Companies are deploying these savings toward debt reduction, capital expenditures, and expansion into newly-legal states. Green Thumb Industries announced in May 2026 it would use tax savings to retire $150 million in high-interest debt and fund entry into Kentucky and Mississippi.

Capital Markets Access

While rescheduling does not automatically grant cannabis companies access to U.S. stock exchanges or traditional banking, it reduces regulatory friction. The Nasdaq and NYSE continue to prohibit listings of companies with direct U.S. cannabis operations, citing federal illegality concerns, but several regional exchanges have expressed interest in creating cannabis-specific listing tiers. Banking access remains limited by the Bank Secrecy Act and federal money laundering statutes, which apply regardless of scheduling. The SAFER Banking Act, reintroduced in the 119th Congress, would provide explicit safe harbor for financial institutions serving state-legal cannabis businesses, but has not yet passed. Rescheduling has not materially changed banking access as of July 2026, though several credit unions and state-chartered banks have expanded cannabis banking programs.

Wholesale Pricing and Market Dynamics

Wholesale cannabis prices declined 15-25% in major markets during 2025-2026, driven partly by increased supply as operators expanded cultivation in anticipation of tax savings. In California, wholesale flower prices averaged $850 per pound in June 2026, down from $1,100 per pound in June 2024. Oregon saw similar declines, with wholesale prices falling to $600 per pound. Rescheduling accelerated consolidation among smaller operators unable to compete at lower price points. The number of active cultivation licenses in Colorado declined from 1,640 in January 2025 to 1,380 in June 2026, a 16% reduction. MSOs with economies of scale and vertical integration gained market share at the expense of single-state operators.

Pharmaceutical Industry Entry

Major pharmaceutical companies signaled increased interest in cannabis following rescheduling. Jazz Pharmaceuticals acquired GW Pharmaceuticals (maker of Epidiolex) for $7.2 billion in 2021, pre-rescheduling. Post-rescheduling, Pfizer announced a partnership with Trulieve in March 2026 to develop FDA-approved cannabis-based medications for chronic pain. Eli Lilly disclosed in May 2026 it had filed three INDs for cannabinoid-based therapies. Pharmaceutical entry creates both opportunities and threats for existing cannabis operators. MSOs possess cultivation and processing expertise but lack drug development and clinical trial infrastructure. Several MSOs have established pharmaceutical partnerships or in-house drug development divisions to compete in an FDA-regulated market.

Insurance and Employee Benefits

Health insurance coverage for medical cannabis remains rare despite rescheduling. Medicare and Medicaid explicitly exclude coverage for Schedule III substances not approved by the FDA, and private insurers have not broadly added cannabis coverage. A few regional insurers in California and Colorado began offering limited medical cannabis coverage in pilot programs during 2026. Workers' compensation insurers in several states now cover medical cannabis for injured workers, a change enabled by rescheduling. New York, New Jersey, and New Mexico explicitly require workers' comp coverage for medical cannabis when recommended by a treating physician for a work-related injury.

What Experts Say About Rescheduling

Medical professionals, policy experts, and industry leaders hold divergent views on rescheduling's significance and limitations. Dr. Bertha Madras, a Harvard Medical School psychobiologist who served on the President's Commission on Combating Drug Addiction and the Opioid Crisis, has consistently opposed rescheduling. In testimony before the House Energy and Commerce Committee in June 2024, Madras said the HHS recommendation "disregarded evidence of cannabis harms, including addiction, psychosis, and impaired driving." She argued that state medical programs do not constitute evidence of accepted medical use under the rigorous standards applied to FDA-approved medications. Dr. Igor Grant, director of the Center for Medicinal Cannabis Research at the University of California San Diego, supported rescheduling in his comments on the NPRM. Grant stated that decades of research demonstrate cannabis efficacy for chronic pain, chemotherapy-induced nausea, and spasticity, meeting any reasonable definition of accepted medical use. He noted that Schedule I status had impeded research by creating regulatory barriers and limiting access to diverse cannabis chemovars. Kevin Sabet, president of Smart Approaches to Marijuana and a former drug policy advisor in the Obama administration, called rescheduling "a half-measure that creates more problems than it solves." According to Sabet, Schedule III status "gives cannabis a veneer of medical legitimacy without requiring the safety and efficacy testing we demand of every other medication." He advocates for maintaining Schedule I status while creating a distinct regulatory pathway for FDA-approved cannabinoid medications. Aaron Smith, co-founder of the National Cannabis Industry Association, described rescheduling as "a meaningful step forward but far from the finish line." Smith noted that rescheduling does not resolve core conflicts between state and federal law, does not provide banking access, and does not address the thousands of individuals incarcerated for cannabis offenses. He continues to advocate for the Marijuana Opportunity Reinvestment and Expungement (MORE) Act, which would deschedule cannabis entirely. Dr. Chinazo Cunningham, a professor of medicine at Albert Einstein College of Medicine who studies medical cannabis for chronic pain, said rescheduling "acknowledges what clinicians have known for years—cannabis has legitimate medical applications." Cunningham emphasized the need for more rigorous clinical trials now that Schedule III status reduces research barriers. She noted that most evidence for medical cannabis comes from observational studies and state program data rather than randomized controlled trials. State-level reactions varied by political orientation. California Attorney General Rob Bonta called rescheduling "long overdue recognition of medical cannabis's therapeutic value and the failure of prohibition." Wyoming Attorney General Bridget Hill stated that rescheduling "does not bind states to accept federal policy missteps" and praised the opt-out provision as "an appropriate recognition of state sovereignty."

What's Next: Timeline and Future Scenarios

Federal cannabis policy faces multiple decision points through 2028 that will determine whether rescheduling represents a final destination or a waypoint toward broader reform.

Near-Term Developments (2026-2027)

The DEA will issue additional guidance on Schedule III implementation, particularly regarding research licensing, import/export permits, and production quotas. The agency announced in June 2026 it would accept applications for bulk manufacture registrations starting in September 2026, allowing commercial-scale production of cannabis for FDA-approved drug development. The IRS will continue refining 280E transition guidance as cannabis businesses file 2025 and 2026 tax returns under mixed Schedule I/III treatment. Tax practitioners expect disputes over the effective date of 280E relief and the treatment of accrued expenses from Schedule I periods. Additional states may exercise opt-out provisions during 2027 legislative sessions. Idaho, Kansas, Nebraska, South Carolina, and Wisconsin have active opt-out bills. The National Conference of State Legislatures projects 3-7 states may ultimately opt out, creating a patchwork of federal Schedule III status with state-level Schedule I treatment.

FDA Approval Pathways (2027-2030)

Multiple pharmaceutical companies and MSOs have filed INDs for cannabis-based drug candidates. The first FDA approval decisions for whole-plant cannabis medications (as opposed to isolated cannabinoids like Epidiolex) are expected in 2028-2029. These approvals would create a legal prescription cannabis market distinct from state medical programs. If FDA-approved cannabis medications reach the market, they will likely be available only through traditional pharmacies, not state-licensed dispensaries. This could create a two-tier system: FDA-approved prescription cannabis covered by insurance but limited to approved indications, and state-program cannabis available for broader conditions but not covered by insurance.

Banking and Financial Services (2027-2028)

The SAFER Banking Act or similar legislation may pass during the 119th or 120th Congress, providing explicit safe harbor for financial institutions serving state-legal cannabis businesses. Senate Banking Committee Chair Sherrod Brown stated in April 2026 that rescheduling "removes one objection to cannabis banking reform but does not solve the underlying problem." The bill has bipartisan support but faces opposition from some progressives who want banking reform tied to social equity provisions. Even without federal legislation, rescheduling may gradually increase banking access as institutions perceive reduced legal risk. The number of financial institutions filing Marijuana-Related Business (MRB) Suspicious Activity Reports with FinCEN increased 12% from Q4 2024 to Q1 2026, suggesting modest expansion of cannabis banking services.

Descheduling and Legalization Efforts (2028+)

Cannabis advocacy organizations continue pushing for complete descheduling through the MORE Act or Cannabis Administration and Opportunity Act. These bills would remove cannabis from the Controlled Substances Act entirely, expunge federal cannabis convictions, and establish a federal regulatory framework similar to alcohol. Political prospects for descheduling depend heavily on the 2028 presidential election and congressional composition. Polling shows 70% public support for cannabis legalization, but descheduling faces opposition from some law enforcement groups, addiction medicine specialists, and social conservatives. International developments may influence U.S. policy. Canada legalized recreational cannabis in 2018, Germany launched a regulated adult-use market in 2024, and several other nations have liberalized cannabis laws. The UN Commission on Narcotic Drugs reclassified cannabis under international treaties in 2020, removing it from the most restrictive category. Continued international normalization may create pressure for further U.S. reform.

Key Dates to Watch

• September 2026: DEA begins accepting bulk manufacture registration applications
• January 2027: State legislatures convene; opt-out bills expected in ID, KS, NE, SC, WI
• April 2027: IRS releases final guidance on 280E transition issues
• June 2027: Senate Banking Committee markup of SAFER Banking Act
• November 2027: First FDA advisory committee meeting on whole-plant cannabis NDA (projected)
• March 2028: DEA five-year review of Schedule III placement (statutorily required)
• November 2028: Presidential election; cannabis policy positions of major candidates

Further Reading and Primary Sources

• DEA Final Rule: Schedules of Controlled Substances: Rescheduling of Marijuana, 90 Fed. Reg. 4588 (January 14, 2025) — https://www.federalregister.gov/
• HHS Recommendation Letter to DEA (August 29, 2023) — https://www.hhs.gov/
• 21 U.S.C. § 812: Schedules of controlled substances (full statutory text) — https://uscode.house.gov/
• Internal Revenue Code § 280E: Expenditures in connection with the illegal sale of drugs — https://www.law.cornell.edu/uscode/
• FDA Guidance: Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research (June 2025) — https://www.fda.gov/
• Congressional Research Service: Marijuana: Medical Use, Retail Sales, and Federal Policy (Updated July 2026) — https://crsreports.congress.gov/
• National Conference of State Legislatures: State Medical Cannabis Laws (interactive map and database) — https://www.ncsl.org/
• Wyoming SF 47: Federal Cannabis Opt-Out Act (2026) — https://www.wyoleg.gov/
• American Medical Association: Report of the Council on Science and Public Health: Cannabis Rescheduling (November 2023) — https://www.ama-assn.org/
• Brookings Institution: The Cannabis Rescheduling Debate: Science, Politics, and Federalism (March 2025) — https://www.brookings.edu/
• RAND Corporation: The Effects of Cannabis Rescheduling on Public Health and Safety (May 2026) — https://www.rand.org/
• Cannabis Industry Journal: 280E Tax Relief Impact Analysis (Q2 2026) — https://www.cannabisindustryjournal.com/